相关实验视频
Updated: Feb 10, 2026

12:08
Multi-scale Analysis of Bacterial Growth Under Stress Treatments
Published on: November 28, 2019
10.0K
明显抗治疗高血压的发生率和预后:使用现实世界的证据进行多状态分析
Htun Teza1, Thunyarat Anothaisintawee1, Thosaphol Limpijankit2
1Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Clinical hypertension
|February 9, 2026
概括
表面抗性高血压 (aRHT) 影响高血压患者每100人年2.61人. 患有aRHT的患者面临显著更高的心血管和并发症风险,以及死亡率.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 公共卫生 公共卫生
背景情况:
- 关于明显抗性高血压 (aRHT) 的发生率和预后的证据有限.
- 高血压管理需要了解尽管服用药物,但血压不受控制的患者的结果.
- 这项研究解决了关于aRHT对心血管和脏健康的影响的知识差距.
研究的目的:
- 在大量高血压患者中估计aRHT的发生率.
- 评估与无RHT患者相比,aRHT患者心血管和并发症的风险.
- 识别aRHT发展的风险因素及其预后影响.
主要方法:
- 一项回顾性队列研究,使用来自114,364名高血压患者 (2010-2024) 的真实数据.
- aRHT定义为不控制的血压在≥3种药物或控制的血压在≥4种药物.
- 多态分析和多变量考克斯回归用于评估疾病进展和风险因素.
主要成果:
- 甲RHT的发生率为每100人年2.61.
- 对aRHT的独立风险因素包括年龄较大,男性性别,肥胖,2型糖尿病,脂质失调以及现有的心血管/并发症.
- 患有aRHT的患者显示冠状动脉疾病 (HR1.80),慢性病 (HR1.93),心力衰竭 (HR4.24) 和全因死亡率 (HR2.84) 的风险显著增加.
结论:
- 患有心血管和脏并发症的高血压患者患有aRHT的风险更高.
- aRHT与预后明显恶化有关,包括增加主要心血管事件的风险,病进展和死亡率.
- 这些发现强调了对明显耐药高血压患者的密集管理的重要性.
更多相关视频
相关概念视频
The Evidence for Evolution
48.4K
Genetic variations accumulating within populations over generations give rise to biological evolution. Evolutionary changes can result in the formation of novel varieties and entire new species. These changes are responsible for the diverse forms of life inhabiting the planet. The evidence for evolution suggests that all living organisms descended from common ancestors.
48.4K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Apparent Weight
9.9K
True weight is the measure of the gravitational force acting on an object. However, if the object accelerates, its measured weight is different from its true weight. Similar observations can be made when the object is submerged in water. An object's weight in water is its apparent weight, which is equal to the difference between its true weight and the buoyant forces.
Consider a person standing on a bathroom scale inside an elevator. If the scale is accurate at rest, its reading equals the...
Consider a person standing on a bathroom scale inside an elevator. If the scale is accurate at rest, its reading equals the...
9.9K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
619
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
619
Prevalence and Incidence
1.9K
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
1.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
479
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
479

